Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

BACKGROUND: Immunotherapies have demonstrated efficacy across a diverse set of tumors supporting further evaluation in glioblastoma. The objective of this study was to evaluate the safety/tolerability and describe immune-mediated effects of nivolumab ± ipilimumab in patients with recurrent glioblast...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Omuro, Antonio, Vlahovic, Gordana, Lim, Michael, Sahebjam, Solmaz, Baehring, Joachim, Cloughesy, Timothy, Voloschin, Alfredo, Ramkissoon, Shakti H, Ligon, Keith L, Latek, Robert, Zwirtes, Ricardo, Strauss, Lewis, Paliwal, Prashni, Harbison, Christopher T, Reardon, David A, Sampson, John H
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Clinical Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892140/
https://ncbi.nlm.nih.gov/pubmed/29106665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox208
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia